

# Adnan Kastrati

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9260358/publications.pdf>

Version: 2024-02-01

681  
papers

91,212  
citations

529

127  
h-index

336

286  
g-index

704  
all docs

704  
docs citations

704  
times ranked

43832  
citing authors

1	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	2.2	7,100
2	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	2.2	5,034
3	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	2.2	4,537
4	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
5	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	2.2	3,048
6	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	2.2	2,687
7	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
8	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	1.4	2,164
9	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. European Heart Journal, 2008, 29, 2909-2945.	2.2	2,128
10	A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery Stents. New England Journal of Medicine, 1996, 334, 1084-1089.	27.0	1,934
11	Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, The, 2007, 370, 937-948.	13.7	1,329
12	Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. New England Journal of Medicine, 2007, 356, 1030-1039.	27.0	1,182
13	Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. JAMA - Journal of the American Medical Association, 2010, 304, 1821.	7.4	980
14	A Randomized Clinical Trial to Evaluate the Safety and Efficacy of a Percutaneous Left Ventricular Assist Device Versus Intra-Aortic Balloon Pumping for Treatment of Cardiogenic Shock Caused by Myocardial Infarction. Journal of the American College of Cardiology, 2008, 52, 1584-1588.	2.8	904
15	Estimated Radiation Dose Associated With Cardiac CT Angiography. JAMA - Journal of the American Medical Association, 2009, 301, 500.	7.4	891
16	Intracoronary Stenting and Angiographic Results. Circulation, 2001, 103, 2816-2821.	1.6	727
17	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	27.0	683
18	Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment <The ISAR-REACT 2 Randomized Trial . JAMA - Journal of the American Medical Association, 2006, 295, 1531.	7.4	682

#	ARTICLE	IF	CITATIONS
19	Radiation Dose Estimates From Cardiac Multislice Computed Tomography in Daily Practice. <i>Circulation</i> , 2006, 113, 1305-1310.	1.6	657
20	Predictive Factors of Restenosis After Coronary Stent Placement. <i>Journal of the American College of Cardiology</i> , 1997, 30, 1428-1436.	2.8	612
21	Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel. <i>Circulation</i> , 2005, 112, 2946-2950.	1.6	605
22	Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2009, 53, 849-856.	2.8	600
23	Association analyses based on false discovery rate implicate new loci for coronary artery disease. <i>Nature Genetics</i> , 2017, 49, 1385-1391.	21.4	571
24	A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2159-2164.	2.8	569
25	A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel. <i>New England Journal of Medicine</i> , 2004, 350, 232-238.	27.0	557
26	Multi-ethnic genome-wide association study for atrial fibrillation. <i>Nature Genetics</i> , 2018, 50, 1225-1233.	21.4	552
27	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2019, 381, 1524-1534.	27.0	543
28	Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 165-71.	7.4	534
29	Effect of Glycoprotein IIb/IIIa Receptor Blockade on Recovery of Coronary Flow and Left Ventricular Function After the Placement of Coronary-Artery Stents in Acute Myocardial Infarction. <i>Circulation</i> , 1998, 98, 2695-2701.	1.6	517
30	Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. <i>Circulation</i> , 2010, 121, 512-518.	1.6	514
31	Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STereo-2) trial. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1283-1288.	2.8	491
32	Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients. <i>New England Journal of Medicine</i> , 2005, 353, 663-670.	27.0	462
33	Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions. <i>Journal of the American College of Cardiology</i> , 2008, 51, 690-697.	2.8	452
34	Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. <i>Journal of the American College of Cardiology</i> , 1998, 32, 1866-1873.	2.8	444
35	Current Treatment of In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2659-2673.	2.8	443
36	Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas GrÅntzig Lecture ESC 2014. <i>European Heart Journal</i> , 2015, 36, 3320-3331.	2.2	441

#	ARTICLE	IF	CITATIONS
37	Vessel Size and Long-Term Outcome After Coronary Stent Placement. <i>Circulation</i> , 1998, 98, 1875-1880.	1.6	433
38	Coronary Stenting plus Platelet Glycoprotein IIb/IIIa Blockade Compared with Tissue Plasminogen Activator in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2000, 343, 385-391.	27.0	428
39	Coding Variation in <i>ANGPTL4</i> , <i>LPL</i> and <i>SVEP1</i> and the Risk of Coronary Disease. <i>New England Journal of Medicine</i> , 2016, 374, 1134-1144.	27.0	427
40	Evaluation of Prolonged Antithrombotic Pretreatment ("Cooling-Off" Strategy) Before Intervention in Patients With Unstable Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 1593-9.	7.4	402
41	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	1.4	402
42	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1619-1629.	2.8	401
43	Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor in Patients With Acute Myocardial Infarction<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1003.	7.4	394
44	5-Year Prognostic Value of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2383-2389.	2.8	380
45	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2019, 14, 1435-1534.	3.2	367
46	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , 2015, 36, 1252-1263.	2.2	366
47	Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. <i>European Heart Journal</i> , 2015, 36, 2147-2159.	2.2	362
48	Impact of P-glycoprotein on clopidogrel absorption. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 486-501.	4.7	361
49	Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. <i>European Heart Journal</i> , 2012, 33, 1214-1222.	2.2	359
50	Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. <i>European Heart Journal</i> , 2008, 30, 916-922.	2.2	353
51	Incidence and predictors of restenosis after coronary stenting in 10,004 patients with surveillance angiography. <i>Heart</i> , 2014, 100, 153-159.	2.9	351
52	Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. <i>Lancet</i> , The, 2013, 381, 461-467.	13.7	347
53	Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. <i>European Heart Journal</i> , 2007, 28, 2706-2713.	2.2	337
54	Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2000, 35, 915-921.	2.8	334

#	ARTICLE	IF	CITATIONS
55	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. New England Journal of Medicine, 2008, 359, 688-696.	27.0	323
56	Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet, The, 2016, 387, 537-544.	13.7	317
57	A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 50, 1373-1380.	2.8	307
58	Abciximab in Patients With Acute ST-Segmentâ€Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading. Circulation, 2009, 119, 1933-1940.	1.6	300
59	Bleeding and stent thrombosis on P2Y<sub>12</sub>-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. European Heart Journal, 2015, 36, 1762-1771.	2.2	297
60	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ, The, 2014, 348, g3859-g3859.	6.0	291
61	Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel. Circulation, 2004, 110, 3627-3635.	1.6	288
62	Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Second-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2013, 6, 1267-1274.	2.9	286
63	Abciximab and Heparin versus Bivalirudin for Nonâ€ST-Elevation Myocardial Infarction. New England Journal of Medicine, 2011, 365, 1980-1989.	27.0	285
64	Restenosis after coronary placement of various stent types. American Journal of Cardiology, 2001, 87, 34-39.	1.6	272
65	Sirolimus-Eluting Stents vs Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2005, 294, 819.	7.4	272
66	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ: British Medical Journal, 2008, 337, a1331-a1331.	2.3	270
67	Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents. Circulation, 2006, 113, 2293-2300.	1.6	266
68	Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thrombosis and Haemostasis, 2008, 99, 121-126.	3.4	265
69	Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet, The, 2015, 386, 655-664.	13.7	261
70	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2018, 53, 34-78.	1.4	261
71	Classification of coronary artery bifurcation lesions and treatments: Time for a consensus!. Catheterization and Cardiovascular Interventions, 2008, 71, 175-183.	1.7	260
72	Impact of the Everolimus-Eluting Stent on Stent Thrombosis. Journal of the American College of Cardiology, 2011, 58, 1569-1577.	2.8	258

#	ARTICLE	IF	CITATIONS
73	Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting More Than 12 Hours From Symptom Onset<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2005, 293, 2865.	7.4	238
74	Prognostic Value of Coronary Computed Tomographic Angiography for Prediction of Cardiac Events in Patients With Suspected Coronary Artery Disease. JACC: Cardiovascular Imaging, 2009, 2, 404-411.	5.3	238
75	Triple Therapy With Aspirin, Prasugrel, and Vitamin K Antagonists in Patients With Drug-Eluting Stent Implantation and an Indication for Oral Anticoagulation. Journal of the American College of Cardiology, 2013, 61, 2060-2066.	2.8	225
76	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. European Heart Journal, 2009, 30, 2714-2721.	2.2	224
77	Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. European Heart Journal, 2007, 28, 443-449.	2.2	222
78	Prevalence of Noncalcified Coronary Plaques by 64-Slice Computed Tomography in Patients With an Intermediate Risk for Significant Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 48, 312-318.	2.8	218
79	Pharmacokinetics of clopidogrel after administration of a high loading dose. Thrombosis and Haemostasis, 2004, 92, 311-316.	3.4	215
80	Standardized Imaging for Aortic Annular Sizing. JACC: Cardiovascular Imaging, 2013, 6, 249-262.	5.3	209
81	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. European Heart Journal, 2009, 30, 2441-2449.	2.2	207
82	Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Circulation, 2012, 125, 1424-1431.	1.6	207
83	Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis. Circulation, 2017, 136, 1007-1021.	1.6	200
84	Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. European Heart Journal, 2006, 27, 260-266.	2.2	198
85	A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. European Heart Journal, 2007, 28, 1814-1819.	2.2	198
86	Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients. Journal of the American College of Cardiology, 2010, 56, 317-318.	2.8	196
87	Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet, The, 2002, 359, 920-925.	13.7	195
88	Influence of lesion length on restenosis after coronary stent placement. American Journal of Cardiology, 1999, 83, 1617-1622.	1.6	194
89	Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents. Journal of the American College of Cardiology, 2010, 55, 2710-2716.	2.8	192
90	Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy. Circulation, 2004, 110, 1916-1919.	1.6	191

#	ARTICLE	IF	CITATIONS
91	Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. European Heart Journal, 2015, 36, 2608-2620.	2.2	187
92	Increased Risk of Restenosis After Placement of Gold-Coated Stents. Circulation, 2000, 101, 2478-2483.	1.6	186
93	Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. European Heart Journal, 2008, 29, 1975-1982.	2.2	182
94	Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2009, 53, 1760-1768.	2.8	180
95	Drug-coated balloon therapy in coronary and peripheral artery disease. Nature Reviews Cardiology, 2014, 11, 13-23.	13.7	180
96	Coronary balloon angioplasty, stents, and scaffolds. Lancet, The, 2017, 390, 781-792.	13.7	179
97	Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss. Circulation, 2006, 113, 273-279.	1.6	176
98	Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis, 2001, 159, 137-144.	0.8	175
99	A Meta-Analysis of 17 Randomized Trials of a Percutaneous Coronary Intervention-Based Strategy in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2008, 52, 894-904.	2.8	175
100	No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. European Heart Journal, 2011, 32, 1605-1613.	2.2	174
101	Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. European Heart Journal, 2011, 32, 32-40.	2.2	173
102	Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents. Journal of the American College of Cardiology, 2006, 47, 708-714.	2.8	172
103	Intracoronary Stenting and Risk for Major Adverse Cardiac Events During the First Month. Circulation, 1998, 98, 104-111.	1.6	168
104	A Randomized Trial Comparing Stenting With Balloon Angioplasty in Small Vessels in Patients With Symptomatic Coronary Artery Disease. Circulation, 2000, 102, 2593-2598.	1.6	168
105	Improved Noninvasive Assessment of Coronary Artery Bypass Grafts With 64-Slice Computed Tomographic Angiography in an Unselected Patient Population. Journal of the American College of Cardiology, 2007, 49, 946-950.	2.8	165
106	Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet, The, 2011, 378, 1071-1078.	13.7	164
107	High-Speed Rotational Atherectomy Versus Modified Balloons Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions. Circulation: Cardiovascular Interventions, 2018, 11, e007415.	3.9	164
108	Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture. JAMA - Journal of the American Medical Association, 2014, 312, 1981.	7.4	162



#	ARTICLE	IF	CITATIONS
109	Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis. <i>Circulation</i> , 2004, 110, 790-795.	1.6	160
110	Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. <i>Lancet</i> , The, 2017, 390, 737-746.	13.7	160
111	Platelets contribute to postnatal occlusion of the ductus arteriosus. <i>Nature Medicine</i> , 2010, 16, 75-82.	30.7	158
112	Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2133-2136.	2.8	156
113	Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 291-299.	2.9	156
114	Pl <sup>A</sup> Polymorphism of Platelet Glycoprotein IIIa and Risk of Restenosis After Coronary Stent Placement. <i>Circulation</i> , 1999, 99, 1005-1010.	1.6	153
115	Early Administration of Reteplase Plus Abciximab vs Abciximab Alone in Patients With Acute Myocardial Infarction Referred for Percutaneous Coronary Intervention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 947.	7.4	149
116	Effectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2007, 49, 616-623.	2.8	149
117	Predictors of Permanent Pacemaker Implantations and New-Onset Conduction Abnormalities With the SAPIEN 3 Balloon-Expandable Transcatheter Heart Valve. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 244-254.	2.9	149
118	Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. <i>American Heart Journal</i> , 2010, 160, 506-512.	2.7	147
119	Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. <i>European Heart Journal</i> , 2016, 37, 1538.1-1549.	2.2	147
120	Predictive Factors and Impact of No Reflow After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 27-33.	3.9	141
121	Sex-Based Analysis of Outcome in Patients With Acute Myocardial Infarction Treated Predominantly With Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 210.	7.4	140
122	Randomized Comparison of a Titanium-Nitride-Oxideâ€‘Coated Stent With a Stainless Steel Stent for Coronary Revascularization. <i>Circulation</i> , 2005, 111, 2617-2622.	1.6	139
123	Therapy-Dependent Influence of Time-to-Treatment Interval on Myocardial Salvage in Patients With Acute Myocardial Infarction Treated With Coronary Artery Stenting or Thrombolysis. <i>Circulation</i> , 2003, 108, 1084-1088.	1.6	138
124	Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1429-1437.	2.8	136
125	Biodegradable Polymer Versus Permanent Polymer Drug-Eluting Stents and Everolimus- Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1325-1331.	2.8	131
126	Non-invasive coronary computed tomographic angiography for patients with suspected coronary artery disease: the Coronary Angiography by Computed Tomography with the Use of a Submillimeter resolution (CACTUS) trial. <i>European Heart Journal</i> , 2007, 28, 3034-3041.	2.2	129



#	ARTICLE	IF	CITATIONS
127	Impact of Body Mass Index on Platelet Aggregation After Administration of a High Loading Dose of 600 mg of Clopidogrel Before Percutaneous Coronary Intervention. American Journal of Cardiology, 2007, 100, 203-205.	1.6	129
128	Coronary Stent Placement in Patients With Acute Myocardial Infarction: Comparison of Clinical and Angiographic Outcome After Randomization to Antiplatelet or Anticoagulant Therapy. Journal of the American College of Cardiology, 1997, 29, 28-34.	2.8	128
129	Haptoglobin Genotype Is Predictive of Major Adverse Cardiac Events in the 1-Year Period After Percutaneous Transluminal Coronary Angioplasty in Individuals With Diabetes. Diabetes Care, 2003, 26, 2628-2631.	8.6	128
130	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet, The, 2013, 382, 1879-1888.	13.7	127
131	Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thrombosis and Haemostasis, 2010, 103, 151-159.	3.4	126
132	Polymer-Free Sirolimus- and Probucol-Eluting Versus New Generation Zotarolimus-Eluting Stents in Coronary Artery Disease. Circulation, 2011, 124, 624-632.	1.6	126
133	Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent Coating. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 748-753.	2.4	125
134	A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. European Heart Journal, 2008, 30, 923-931.	2.2	123
135	Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2001, 357, 2085-2089.	13.7	122
136	Erythropoietin in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2010, 3, 408-413.	3.9	122
137	Influence of stent design on 1-year outcome after coronary stent placement: A randomized comparison of five stent types in 1,147 unselected patients. Catheterization and Cardiovascular Interventions, 2000, 50, 290-297.	1.7	121
138	Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials. International Journal of Cardiology, 2008, 126, 37-44.	1.7	121
139	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). European Heart Journal, 2020, 41, 3715-3728.	2.2	121
140	Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease. Circulation: Cardiovascular Interventions, 2012, 5, 582-589.	3.9	117
141	Prognostic Value of the Modified American College of Cardiology/American Heart Association Stenosis Morphology Classification for Long-Term Angiographic and Clinical Outcome After Coronary Stent Placement. Circulation, 1999, 100, 1285-1290.	1.6	116
142	Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. European Heart Journal, 2012, 33, 3078-3087.	2.2	115
143	Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. European Heart Journal, 2005, 26, 1262-1268.	2.2	113
144	Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. Journal of the American College of Cardiology, 2000, 36, 2168-2173.	2.8	109

#	ARTICLE	IF	CITATIONS
145	Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2011-2022.	2.8	109
146	Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. <i>Clinica Chimica Acta</i> , 2018, 476, 130-138.	1.1	109
147	2-Year Clinical and Angiographic Outcomes From a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents Versus Polymer-Based Cypher and Endeavor, Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2536-2543.	2.8	108
148	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016, 182, 125-134.	2.7	108
149	Prospective Evaluation of <sup>18</sup> F-Fluorodeoxyglucose Uptake in Postischemic Myocardium by Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging as a Prognostic Marker of Functional Outcome. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004316.	2.6	107
150	Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. <i>European Heart Journal</i> , 2005, 26, 1475-1481.	2.2	106
151	Gender and restenosis after coronary artery stenting. <i>European Heart Journal</i> , 2003, 24, 1523-1530.	2.2	105
152	Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. <i>American Heart Journal</i> , 2007, 154, 3-11.	2.7	103
153	Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. <i>American Heart Journal</i> , 2004, 147, 457-462.	2.7	102
154	Evolution of Left Ventricular Ejection Fraction and its Relationship to Infarct Size After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 149-156.	2.8	100
155	Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis. <i>JAMA Cardiology</i> , 2017, 2, 1079.	6.1	99
156	Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. <i>European Heart Journal</i> , 2015, 36, 94-99.	2.2	98
157	Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1332-1340.	2.9	98
158	Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. <i>Circulation</i> , 2019, 139, 325-333.	1.6	97
159	Drug-Eluting Stents for Revascularization of Infrapopliteal Arteries. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1284-1293.	2.9	95
160	Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. <i>American Heart Journal</i> , 2004, 147, 317-322.	2.7	94
161	P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 199-204.	1.0	94
162	Antiplatelet therapy after percutaneous coronary intervention. <i>EuroIntervention</i> , 2022, 17, e1371-e1396.	3.2	94

#	ARTICLE	IF	CITATIONS
163	Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. <i>Thrombosis and Haemostasis</i> , 2006, 95, 910-911.	3.4	93
164	Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2014, 35, 2285-2294.	2.2	93
165	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	2.2	93
166	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2664-2678.	2.8	93
167	Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes. <i>European Heart Journal</i> , 2008, 29, 2868-2876.	2.2	92
168	Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. <i>American Heart Journal</i> , 2007, 154, 688-693.	2.7	91
169	Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. <i>American Heart Journal</i> , 2009, 157, 620-624.e2.	2.7	91
170	Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular Causes in Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 904-916.	2.8	91
171	Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. <i>Thrombosis and Haemostasis</i> , 2009, 101, 714-9.	3.4	91
172	Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005, 45, 828-831.	2.8	90
173	Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. <i>American Heart Journal</i> , 2011, 161, 68-75.	2.7	90
174	Association between C-Reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. <i>American Journal of Medicine</i> , 2003, 114, 715-722.	1.5	88
175	Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2005, 93, 35-39.	3.4	88
176	Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 863-871.	2.8	88
177	High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2259-2268.	2.8	88
178	Vessel Size and Outcome After Coronary Drug-Eluting Stent Placement. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1304-1309.	2.8	87
179	Prognostic Value of Coronary Computed Tomographic Angiography in Comparison With Calcium Scoring and Clinical Risk Scores. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 16-23.	2.6	87
180	Early Resolution of ST-Segment Elevation Correlates With Myocardial Salvage Assessed by Tc-99m Sestamibi Scintigraphy in Patients With Acute Myocardial Infarction After Mechanical or Thrombolytic Reperfusion Therapy. <i>Circulation</i> , 2002, 105, 2946-2949.	1.6	86

#	ARTICLE	IF	CITATIONS
181	Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. <i>Clinical Chemistry</i> , 2002, 48, 1377-82.	3.2	86
182	Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 877-884.	2.9	85
183	Gamma-glutamyl transferase and cardiovascular disease. <i>Annals of Translational Medicine</i> , 2016, 4, 481-481.	1.7	85
184	Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy. <i>European Heart Journal</i> , 2011, 32, 1121-1133.	2.2	84
185	Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategyâ€”Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 91-100.	2.4	84
186	Functional Characterization of the <i>GUCY1A3</i> Coronary Artery Disease Risk Locus. <i>Circulation</i> , 2017, 136, 476-489.	1.6	84
187	Multicenter Comparison of Novel Self-Expanding Versus Balloon-Expandable Transcatheter Heartâ€”Valves. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2078-2087.	2.9	84
188	Interlesion Dependence of the Risk for Restenosis in Patients With Coronary Stent Placement in Multiple Lesions. <i>Circulation</i> , 1998, 97, 2396-2401.	1.6	83
189	ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2010, 31, 2482-2491.	2.2	82
190	Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. <i>European Heart Journal</i> , 2004, 25, 1898-1902.	2.2	80
191	Drug-Coated Balloon Versus Plain Balloonâ€”Angioplasty for the Treatment ofâ€”Femoropopliteal Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1731-1742.	2.9	80
192	Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. <i>Clinical Endocrinology</i> , 2008, 68, 660-665.	2.4	78
193	Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. <i>European Heart Journal</i> , 2010, 31, 1205-1211.	2.2	75
194	Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2015, 36, 3202-3210.	2.2	75
195	Operator volume and outcome of patients undergoing coronary stent placement. <i>Journal of the American College of Cardiology</i> , 1998, 32, 970-976.	2.8	73
196	Prognostic Value of Uric Acid in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2012, 109, 1260-1265.	1.6	72
197	Emergency coronary stenting for dissection during percutaneous transluminal coronary angioplasty: Angiographic follow-up after stenting and after repeat angioplasty of the stented segment. <i>Journal of the American College of Cardiology</i> , 1994, 23, 1053-1060.	2.8	71
198	Tissue Characterization After Drug-Eluting Stent Implantation Using Optical Coherence Tomography. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1376-1383.	2.4	70

#	ARTICLE	IF	CITATIONS
199	Late Restenosis in Patients Receiving a Polymer-Coated Sirolimus-Eluting Stent. <i>Annals of Internal Medicine</i> , 2005, 143, 392.	3.9	70
200	Influence of Balloon Pressure During Stent Placement in Native Coronary Arteries on Early and Late Angiographic and Clinical Outcome. <i>Circulation</i> , 1999, 100, 918-923.	1.6	69
201	Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2008, 52, 512-517.	2.8	69
202	Zotarolimus- Versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2075-2082.	2.8	69
203	Association of Transforming Growth Factor- $\beta$ 1 Gene Polymorphisms With Myocardial Infarction in Patients With Angiographically Proven Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1114-1119.	2.4	68
204	Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1193-1200.	3.4	68
205	Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction. <i>Journal of Nuclear Medicine</i> , 2004, 45, 725-9.	5.0	68
206	Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Patients With Chronic Stable Angina. <i>Circulation</i> , 2005, 112, 2102-2107.	1.6	67
207	Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. <i>American Journal of Cardiology</i> , 2005, 95, 553-557.	1.6	66
208	Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102,735 patients. <i>European Heart Journal</i> , 2017, 38, 3160-3172.	2.2	66
209	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , 2019, 40, 2070-2085.	2.2	64
210	Clinical and angiographic follow-up after balloon angioplasty with provisional stenting for coronary in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 48, 151-156.	1.7	63
211	Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. <i>European Heart Journal</i> , 2006, 27, 2524-2529.	2.2	63
212	Drug-Eluting Stents in Percutaneous Coronary Intervention. <i>Drug Safety</i> , 2009, 32, 749-770.	3.2	63
213	High platelet reactivity and clinical outcome – Fact and fiction. <i>Thrombosis and Haemostasis</i> , 2011, 106, 191-202.	3.4	63
214	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	63
215	State of the art: coronary artery stents – past, present and future. <i>EuroIntervention</i> , 2017, 13, 706-716.	3.2	63
216	HPA-1 and HPA-3 Polymorphisms of the Platelet Fibrinogen Receptor and Coronary Artery Disease and Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 2000, 83, 559-562.	3.4	62

#	ARTICLE	IF	CITATIONS
217	Mechanical Reperfusion and Long-term Mortality in Patients With Acute Myocardial Infarction Presenting 12 to 48 Hours From Onset of Symptoms. JAMA - Journal of the American Medical Association, 2009, 301, 487.	7.4	62
218	Overexpansion of the SAPIEN 3 Transcatheter Heart Valve. JACC: Cardiovascular Interventions, 2015, 8, 2041-2043.	2.9	61
219	Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. European Heart Journal, 2019, 40, 2432-2440.	2.2	61
220	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. EuroIntervention, 2016, 11, 1372-137.	3.2	60
221	Insertion/Deletion Polymorphism of the Angiotensin I-Converting Enzyme Gene Is Not Associated With Restenosis After Coronary Stent Placement. Circulation, 2000, 102, 197-202.	1.6	58
222	Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. Journal of the American College of Cardiology, 2003, 41, 925-929.	2.8	58
223	Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: A randomized double-blind controlled trial. Catheterization and Cardiovascular Interventions, 2005, 65, 374-380.	1.7	58
224	A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy. Journal of the American College of Cardiology, 2004, 43, 734-741.	2.8	57
225	The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Biomaterials, 2009, 30, 632-637.	11.4	57
226	Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. European Heart Journal, 2010, 31, 582-587.	2.2	57
227	Long-Term Outcomes After MitraClip Implantation According to the Presence or Absence of EVEREST Inclusion Criteria. American Journal of Cardiology, 2017, 119, 1255-1261.	1.6	57
228	PIA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. Journal of the American College of Cardiology, 2000, 36, 84-89.	2.8	56
229	Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. Journal of the American College of Cardiology, 2002, 40, 882-889.	2.8	56
230	A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. Journal of the American College of Cardiology, 2004, 44, 2073-2079.	2.8	55
231	One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. European Heart Journal, 2008, 29, 455-461.	2.2	55
232	A Double-Blind, Randomized Study on Prevention and Existence of a Rebound Phenomenon of Platelets After Cessation of Clopidogrel Treatment. Journal of the American College of Cardiology, 2010, 55, 558-565.	2.8	55
233	Effect of Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention. American Journal of Cardiology, 2011, 107, 871-878.	1.6	55
234	Everolimus-Eluting Versus Sirolimus-Eluting Stents. Circulation: Cardiovascular Interventions, 2011, 4, 371-377.	3.9	55



#	ARTICLE	IF	CITATIONS
235	Association of uric acid with mortality in patients with stable coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 1780-1786.	3.4	55
236	Fluoroscopy-Guided Aortic Root Imaging for TAVR. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 274-275.	5.3	55
237	Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. <i>American Heart Journal</i> , 2005, 150, 344-350.	2.7	54
238	Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction. <i>European Heart Journal</i> , 2006, 27, 1900-1907.	2.2	54
239	Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. <i>American Journal of Cardiology</i> , 2004, 93, 1201-1206.	1.6	53
240	Peak Cardiac Troponin-T Level, Scintigraphic Myocardial Infarct Size and One-Year Prognosis in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2010, 106, 1212-1217.	1.6	53
241	Prognostic Value of Access and Non-Access Sites Bleeding After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 354-361.	3.9	53
242	Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. <i>Cardiovascular Research</i> , 2005, 68, 483-492.	3.8	52
243	High-Sensitivity Troponin T Level and Angiographic Severity of Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2011, 108, 639-643.	1.6	52
244	Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 784-792.	2.9	52
245	Pre-treatment with P2Y <sub>12</sub> inhibitors in ACS patients: who, when, why, and which agent?. <i>European Heart Journal</i> , 2016, 37, 1284-1295.	2.2	52
246	Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1973-1982.	2.8	52
247	Statin treatment following coronary artery stenting and one-year survival. <i>Journal of the American College of Cardiology</i> , 2002, 40, 854-861.	2.8	51
248	Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. <i>European Heart Journal</i> , 2008, 30, 290-296.	2.2	51
249	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 674-684.	2.9	51
250	Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Balloon-Expandable Transcatheter Heart Valve. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1809-1816.	2.9	50
251	Tumor necrosis factor- $\alpha$ , lymphotoxin- $\alpha$ , and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. <i>Cytokine</i> , 2003, 24, 161-171.	3.2	49
252	10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2020, 76, 146-158.	2.8	49



#	ARTICLE	IF	CITATIONS
253	Differential Healing Responses in Polymer- and Nonpolymer-Based Sirolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2008, 1, 535-544.	2.9	48
254	Circulating homocysteine levels in patients with type 2 diabetes mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 66-73.	2.6	48
255	Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. American Heart Journal, 2011, 162, 518-526.e5.	2.7	48
256	Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: Final results of the intracoronary stenting and angiographic restenosis "test equivalence between two drug-eluting stents (ISAR-TEST) trial. Catheterization and Cardiovascular Interventions, 2013, 81, E23-8.	1.7	47
257	Predictors for long-term survival after transcatheter edge-to-edge mitral valve repair. Journal of Interventional Cardiology, 2017, 30, 226-233.	1.2	47
258	Bimodal Distribution of Angiographic Measures of Restenosis Six Months After Coronary Stent Placement. Circulation, 1997, 96, 3880-3887.	1.6	47
259	Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. EuroIntervention, 2013, 9, 797-802.	3.2	47
260	Clopidogrel therapy in patients undergoing coronary stenting: Value of a high-loading-dose regimen. Catheterization and Cardiovascular Interventions, 2002, 55, 436-441.	1.7	46
261	Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. American Heart Journal, 2008, 155, 356-360.	2.7	46
262	Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clinical Research in Cardiology, 2012, 101, 461-467.	3.3	46
263	Comparative in-vitro validation of eight first- and second-generation quantitative coronary angiography systems. Coronary Artery Disease, 1997, 8, 83-90.	0.7	45
264	Tissue factor promotor polymorphism $\sim 603$ A/G is associated with myocardial infarction. Atherosclerosis, 2004, 177, 189-191.	0.8	45
265	Drug-eluting stents for diabetes mellitus. Journal of the American College of Cardiology, 2005, 45, 479-483.	2.8	45
266	Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. European Heart Journal, 2008, 29, 1504-1509.	2.2	45
267	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. European Heart Journal, 2018, 39, 1591-1601.	2.2	45
268	A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. American Heart Journal, 2004, 148, 105.	2.7	44
269	One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. European Heart Journal, 2005, 26, 1379-1384.	2.2	44
270	Vascular access and closure in coronary angiography and percutaneous intervention. Nature Reviews Cardiology, 2013, 10, 27-40.	13.7	44

#	ARTICLE	IF	CITATIONS
271	Impact of Coronary Anatomy and Stenting Technique on Long-Term Outcome After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2014, 7, 29-36.	2.9	44
272	Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients with Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. Thrombosis Research, 2014, 134, 558-564.	1.7	44
273	Optimal Imaging for Guiding TAVR: Transesophageal or Transthoracic Echocardiography, or Just Fluoroscopy?. JACC: Cardiovascular Imaging, 2015, 8, 361-370.	5.3	44
274	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes. Annals of Internal Medicine, 2020, 173, 436-444.	3.9	44
275	Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease. JAMA Cardiology, 2021, 6, 753.	6.1	44
276	Duration of Dual Antiplatelet Therapy and Long-Term Clinical Outcome After Coronary Drug-Eluting Stent Implantation. Circulation: Cardiovascular Interventions, 2012, 5, 381-391.	3.9	43
277	Safety and Efficacy of a Potential Treatment Algorithm by Using Manual Compression Repair and Ultrasound-Guided Thrombin Injection for the Management of Iatrogenic Femoral Artery Pseudoaneurysm in a Large Patient Cohort. Circulation: Cardiovascular Interventions, 2014, 7, 207-215.	3.9	43
278	Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. Journal of the American College of Cardiology, 2001, 37, 2066-2073.	2.8	42
279	Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial. American Heart Journal, 2003, 146, 882-886.	2.7	42
280	Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. American Heart Journal, 2013, 166, 534-540.	2.7	42
281	Relation of Fibrinogen Level With Cardiovascular Events in Patients With Coronary Artery Disease. American Journal of Cardiology, 2013, 111, 804-810.	1.6	42
282	Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH). Circulation, 2017, 135, 2218-2226.	1.6	42
283	CD14 gene $\sim 159C/T$ polymorphism is not associated with coronary artery disease and myocardial infarction. American Heart Journal, 2002, 143, 971-976.	2.7	41
284	No Replication of Association Between Estrogen Receptor $\beta$ Gene Polymorphisms and Susceptibility to Myocardial Infarction in a Large Sample of Patients of European Descent. Circulation, 2005, 112, 2138-2142.	1.6	41
285	Prognostic value of late gadolinium enhancement in cardiovascular magnetic resonance imaging after acute ST-elevation myocardial infarction in comparison with single-photon emission tomography using Tc99m-Sestamibi. European Heart Journal Cardiovascular Imaging, 2014, 15, 216-225.	1.2	41
286	A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Thrombosis and Haemostasis, 2014, 112, 342-351.	3.4	41
287	Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2020, 76, 2436-2446.	2.8	41
288	Prognostic Value of a High On-Clopidogrel Treatment Platelet Reactivity in Bivalirudin Versus Abciximab Treated Non-ST-Segment Elevation Myocardial Infarction Patients. Journal of the American College of Cardiology, 2012, 60, 369-377.	2.8	40

#	ARTICLE	IF	CITATIONS
289	Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: A meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. International Journal of Cardiology, 2013, 168, 4002-4009.	1.7	40
290	Uric acid and prognosis in angiography-proven coronary artery disease. European Journal of Clinical Investigation, 2013, 43, 256-266.	3.4	40
291	Percutaneous edge-to-edge repair of the mitral valve in patients with degenerative versus functional mitral regurgitation. Catheterization and Cardiovascular Interventions, 2014, 84, 137-146.	1.7	40
292	Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. International Journal of Cardiology, 2017, 244, 93-99.	1.7	40
293	Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. European Heart Journal, 2019, 40, 167-176.	2.2	40
294	Platelet function in clopidogrel-treated patients with acute coronary syndrome. Blood Coagulation and Fibrinolysis, 2007, 18, 335-339.	1.0	39
295	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2017, 52, 206-217.	1.4	39
296	Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials. Clinical Research in Cardiology, 2011, 100, 561-570.	3.3	38
297	Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. EuroIntervention, 2015, 11, 196-203.	3.2	38
298	Risk of combining PPIs with thienopyridines: fact or fiction?. Lancet, The, 2009, 374, 952-954.	13.7	37
299	Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thrombosis and Haemostasis, 2011, 105, 107-112.	3.4	37
300	No Association of ABCB1 C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting. Circulation: Cardiovascular Interventions, 2012, 5, 82-88.	3.9	37
301	The Assessment of Area at Risk and Myocardial Salvage After Coronary Revascularization in Acute Myocardial Infarction. JACC: Cardiovascular Imaging, 2013, 6, 358-369.	5.3	37
302	Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. Catheterization and Cardiovascular Interventions, 2007, 70, 359-365.	1.7	36
303	Patterns of Presentation and Outcomes of Patients with Acute Coronary Syndromes. Cardiology, 2009, 113, 198-206.	1.4	36
304	Alkaline phosphatase and prognosis in patients with coronary artery disease. European Journal of Clinical Investigation, 2017, 47, 378-387.	3.4	36
305	Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. European Heart Journal, 2007, 28, 968-973.	2.2	35
306	Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence. Human Molecular Genetics, 2008, 17, 1120-1126.	2.9	35

#	ARTICLE	IF	CITATIONS
307	Neoatherosclerosis in Patients With Coronary Stent Thrombosis. JACC: Cardiovascular Interventions, 2018, 11, 1340-1350.	2.9	35
308	Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. EuroIntervention, 2018, 13, 1565-1573.	3.2	35
309	Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. European Heart Journal, 2003, 24, 1128-1133.	2.2	34
310	Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?. Journal of the American College of Cardiology, 2007, 49, 1265-1271.	2.8	34
311	Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clinical Research in Cardiology, 2010, 99, 345-357.	3.3	34
312	Management of in-stent restenosis. EuroIntervention, 2022, 18, e103-e123.	3.2	34
313	Long-term outcome after coronary stenting. Current Controlled Trials in Cardiovascular Medicine, 2000, 1, 48.	1.5	33
314	Genetic risk factors and restenosis after percutaneous coronary interventions. Herz, 2000, 25, 34-46.	1.1	33
315	Comparison of C-Reactive Protein Levels Before and After Coronary Stenting and Restenosis Among Patients Treated With Sirolimus-Eluting Versus Bare Metal Stents. American Journal of Cardiology, 2005, 95, 1238-1240.	1.6	33
316	Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions. Circulation, 2006, 114, 2040-2046.	1.6	33
317	Comparative efficacy of 2 zotarolimus-eluting stent generations: Resolute versus endeavor stents in patients with coronary artery disease. American Heart Journal, 2013, 165, 80-86.	2.7	33
318	Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography. International Journal of Cardiovascular Imaging, 2014, 30, 495-504.	1.5	33
319	Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTEMI-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1368-1378.	2.2	33
320	Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thrombosis and Haemostasis, 2007, 98, 852-7.	3.4	33
321	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 19 Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2015, 116, 845-852.	1.6	32
322	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 1890-1901.	2.9	32
323	Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2018, 11, e006752.	3.9	32
324	Genetically modulated educational attainment and coronary disease risk. European Heart Journal, 2019, 40, 2413-2420.	2.2	32

#	ARTICLE	IF	CITATIONS
325	Previous Cytomegalovirus Infection and Risk of Coronary Thrombotic Events After Stent Placement. <i>Circulation</i> , 2000, 101, 11-13.	1.6	31
326	ABO locus O1 allele and risk of myocardial infarction. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 61-67.	1.0	31
327	Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. <i>Clinica Chimica Acta</i> , 2005, 360, 178-186.	1.1	31
328	Reproducibility of area at risk assessment in acute myocardial infarction by T1- and T2-mapping sequences in cardiac magnetic resonance imaging in comparison to Tc99m-sestamibi SPECT. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 1357-1363.	1.5	31
329	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 28-38.	2.9	31
330	Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. <i>European Heart Journal</i> , 2003, 24, 820-827.	2.2	30
331	Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms. <i>American Heart Journal</i> , 2006, 152, 1133-1139.	2.7	30
332	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 829-844.	13.7	30
333	N-Terminal Pro-Brain Natriuretic Peptide on Admission in Patients With Acute Myocardial Infarction and Correlation With Scintigraphic Infarct Size, Efficacy of Reperfusion, and Prognosis. <i>American Journal of Cardiology</i> , 2006, 97, 1151-1156.	1.6	29
334	No Association of Chromosome 9p21.3 Variation With Clinical and Angiographic Outcomes After Placement of Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1149-1155.	2.9	29
335	Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 705-712.	3.9	29
336	Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. <i>International Journal of Cardiology</i> , 2013, 168, 5162-5166.	1.7	29
337	Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 182-189.	1.7	29
338	Drug-Coated Balloons for Revascularization of Infrapopliteal Arteries. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1072-1080.	2.9	29
339	Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 42.	0.6	29
340	Randomized Comparison of Intensified and Standard P2Y <sub>12</sub> -Receptor-Inhibition Before Elective Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008649.	3.9	29
341	Primary intracoronary stenting in acute myocardial infarction: Long-term clinical and angiographic follow-up and risk factor analysis. <i>American Heart Journal</i> , 2000, 139, 208-216.	2.7	28
342	G protein beta 3 subunit 825T allele carriage and risk of coronary artery disease. <i>Atherosclerosis</i> , 2003, 167, 135-139.	0.8	28

#	ARTICLE	IF	CITATIONS
343	No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. <i>Genetics in Medicine</i> , 2007, 9, 123-129.	2.4	28
344	Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. <i>Thrombosis and Haemostasis</i> , 2010, 104, 626-632.	3.4	28
345	Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. <i>American Heart Journal</i> , 2011, 161, 605-610.	2.7	28
346	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 68-76.	2.9	28
347	Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2569-2571.	2.8	28
348	Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 46-52.	1.0	27
349	Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: Case-control study and a meta-analysis. <i>Atherosclerosis</i> , 2010, 208, 171-176.	0.8	27
350	Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1190-1197.	3.4	27
351	The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry. <i>Thrombosis Research</i> , 2015, 136, 87-93.	1.7	27
352	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2238-2247.	2.9	27
353	Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1005-1012.	2.8	26
354	Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. <i>FASEB Journal</i> , 2004, 18, 1285-1287.	0.5	26
355	Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. <i>European Heart Journal</i> , 2007, 28, 2720-2725.	2.2	26
356	Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 156-162.	0.8	26
357	Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1989-1999.	3.4	26
358	Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI: Design and Rationale of the Randomized ISAR-PLASTER Trial. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1539-1545.	3.4	26
359	Ticagrelor or Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 2329-2337.	1.6	26
360	Usefulness of intracoronary brachytherapy for in-stent restenosis with a 188Re liquid-filled balloon. <i>American Journal of Cardiology</i> , 2001, 87, 463-466.	1.6	25



#	ARTICLE	IF	CITATIONS
361	Prevention of Restenosis by Systemic Drug Therapy. <i>Circulation</i> , 2005, 112, 2759-2761.	1.6	25
362	Prognostic Value of Kidney Function in Patients With ST-Elevation and Non-“ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. <i>American Journal of Kidney Diseases</i> , 2009, 54, 830-839.	1.9	25
363	Bleeding After Percutaneous Coronary Intervention With Bivalirudin or Unfractionated Heparin and One-Year Mortality. <i>American Journal of Cardiology</i> , 2010, 105, 163-167.	1.6	25
364	Drug-eluting stents perform better than bare metal stents in small coronary vessels: A meta-analysis of randomised and observational clinical studies with mid-term follow up. <i>International Journal of Cardiology</i> , 2012, 161, 73-82.	1.7	25
365	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	6.1	25
366	Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. <i>American Journal of Cardiology</i> , 1999, 84, 987-991.	1.6	24
367	Cangrelor “A Champion Lost in Translation?”. <i>New England Journal of Medicine</i> , 2009, 361, 2382-2384.	27.0	24
368	A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. <i>American Heart Journal</i> , 2011, 162, 740-747.	2.7	24
369	Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2015, 104, 887-901.	3.3	24
370	Homocysteine Status and Polymorphisms of Methylenetetrahydrofolate Reductase Are Not Associated With Restenosis After Stenting in Coronary Arteries. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 2229-2234.	2.4	23
371	The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. <i>European Heart Journal</i> , 2004, 25, 335-341.	2.2	23
372	A Randomized, Double-Blind, Placebo-Controlled Trial on Restenosis Prevention by the Receptor Tyrosine Kinase Inhibitor Imatinib. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1999-2003.	2.8	23
373	Association of variants in the BAT1-NFKBIL1-LTA genomic region with protection against myocardial infarction in Europeans. <i>Human Molecular Genetics</i> , 2007, 16, 1821-1827.	2.9	23
374	Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2009, 101, 340-344.	3.4	23
375	Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. <i>Heart and Vessels</i> , 2010, 25, 27-34.	1.2	23
376	The chromosome 9p21 region and myocardial infarction in a European population. <i>Atherosclerosis</i> , 2011, 217, 220-226.	0.8	23
377	Intra-aortic balloon counterpulsation in patients with acute myocardial infarction without cardiogenic shock. A meta-analysis of randomized trials. <i>American Heart Journal</i> , 2012, 164, 58-65.e1.	2.7	23
378	Pharmacological inhibition of coronary restenosis: systemic and local approaches. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2155-2171.	1.8	23



#	ARTICLE	IF	CITATIONS
379	Acute and Midterm Outcome After MitraClip Therapy in Patients With Severe Mitral Regurgitation and Left Ventricular Dysfunction. American Journal of Cardiology, 2015, 116, 749-756.	1.6	23
380	Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. American Journal of Cardiology, 2001, 88, 1120-1124.	1.6	22
381	Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. American Journal of Medicine, 2002, 112, 13-18.	1.5	22
382	Value of serum ferritin and soluble transferrin receptor for prediction of coronary artery disease and its clinical presentations. Atherosclerosis, 2004, 174, 105-110.	0.8	22
383	One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. Clinical Research in Cardiology, 2010, 99, 795-802.	3.3	22
384	4C/5G polymorphism and haplotypes of SERPINE1 in atherosclerotic diseases of coronary arteries. Thrombosis and Haemostasis, 2010, 103, 1170-1180.	3.4	22
385	Endovascular Therapy for Steno-Occlusive Subclavian and Innominate Artery Disease. Circulation Journal, 2015, 79, 537-543.	1.6	22
386	Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets, 2015, 26, 53-58.	2.3	22
387	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 53-65.	2.9	22
388	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. European Heart Journal, 2018, 39, e1-e33.	2.2	22
389	Emergency extracorporeal membrane oxygenation in transcatheter aortic valve implantation: A two-center experience of incidence, outcome and temporal trends from 2010 to 2015. Catheterization and Cardiovascular Interventions, 2018, 92, 149-156.	1.7	22
390	Outcome after new generation single-layer polytetrafluoroethylene-covered stent implantation for the treatment of coronary artery perforation. Catheterization and Cardiovascular Interventions, 2019, 93, 912-920.	1.7	22
391	Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction. Journal of Nuclear Medicine, 2005, 46, 1782-8.	5.0	22
392	Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: Results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. American Heart Journal, 2007, 154, 158.e1-158.e7.	2.7	21
393	Bioresorbable Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2015, 8, 198-200.	2.9	21
394	Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2015, 39, 35-42.	2.1	21
395	Subphenotyping of Patients With Aortic Stenosis by Unsupervised Agglomerative Clustering of Echocardiographic and Hemodynamic Data. JACC: Cardiovascular Interventions, 2021, 14, 2127-2140.	2.9	21
396	Angiotensin converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene. Journal of the American College of Cardiology, 2003, 41, 1957-1961.	2.8	20

#	ARTICLE	IF	CITATIONS
397	Lack of support for association between common variation in TNFSF4 and myocardial infarction in a German population. <i>Nature Genetics</i> , 2008, 40, 1386-1387.	21.4	20
398	Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1142-1148.	2.9	20
399	Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. <i>American Heart Journal</i> , 2010, 160, 355-361.	2.7	20
400	New Roads, New Ruts. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 165-167.	2.9	20
401	Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 84-89.	0.8	20
402	A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial. <i>American Heart Journal</i> , 2016, 179, 69-76.	2.7	20
403	Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. <i>EuroIntervention</i> , 2015, 10, 1425-1431.	3.2	20
404	Proximal occlusion versus distal filter for cerebral protection during carotid stenting: updated meta-analysis of randomised and observational MRI studies. <i>EuroIntervention</i> , 2015, 11, 238-246.	3.2	20
405	G Protein $\beta 3$ subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement. <i>Atherosclerosis</i> , 2000, 149, 151-155.	0.8	19
406	Previous Cytomegalovirus Infection and Restenosis After Coronary Stent Placement. <i>Circulation</i> , 2001, 104, 1135-1139.	1.6	19
407	4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. <i>American Heart Journal</i> , 2003, 146, 855-861.	2.7	19
408	Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting. <i>European Heart Journal</i> , 2004, 25, 1635-1640.	2.2	19
409	Is Diabetes the Achilles' Heel of Limus-Eluting Stents?. <i>Circulation</i> , 2011, 124, 869-872.	1.6	19
410	CYP2C19 Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 514-521.	3.9	19
411	Bleeding complications in patients undergoing percutaneous coronary interventions. <i>Coronary Artery Disease</i> , 2014, 25, 247-257.	0.7	19
412	Gamma-glutamyl transferase and prognosis in patients with coronary artery disease. <i>Clinica Chimica Acta</i> , 2016, 452, 155-160.	1.1	19
413	ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. <i>Cardiology Journal</i> , 2012, 19, 61-69.	1.2	19
414	Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. <i>Clinical Research in Cardiology</i> , 2016, 105, 575-584.	3.3	18

#	ARTICLE	IF	CITATIONS
415	Alanine aminotransferaseâ€”a marker of cardiovascular risk at high and low activity levels. <i>Journal of Laboratory and Precision Medicine</i> , 0, 4, 29-29.	1.1	18
416	Clinical and angiographic outcome after stent placement for chronic coronary occlusion. <i>American Journal of Cardiology</i> , 1998, 82, 803-806.	1.6	17
417	Haptoglobin Gene Subtyping by Restriction Enzyme Analysis. <i>Clinical Chemistry</i> , 2003, 49, 1937-1940.	3.2	17
418	Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. <i>American Heart Journal</i> , 2005, 150, 550-556.	2.7	17
419	Fiveâ€”year clinical outcomes of sirolimusâ€”eluting versus paclitaxelâ€”eluting stents in highâ€”risk patients. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 494-501.	1.7	17
420	Comparison of Prasugrel and Bivalirudin vs Clopidogrel and Heparin in Patients With ST-Segment Elevation Myocardial Infarction: Design and Rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Trial. <i>Clinical Cardiology</i> , 2014, 37, 270-276.	1.8	17
421	Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 1087-1095.	1.5	17
422	Relation of Body Mass Index to Bleeding During Percutaneous Coronary Interventions. <i>American Journal of Cardiology</i> , 2015, 115, 434-440.	1.6	17
423	Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). <i>American Journal of Cardiology</i> , 2016, 117, 532-538.	1.6	17
424	Reperfusion injury in ST-segment elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2017, 28, 253-262.	0.7	17
425	Sex differences in the outcome after percutaneous coronary intervention â€” A propensity matching analysis. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 101-107.	0.8	17
426	Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. <i>Clinica Chimica Acta</i> , 2011, 412, 1350-1356.	1.1	16
427	Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction. <i>Thrombosis Research</i> , 2011, 127, 119-121.	1.7	16
428	Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. <i>Clinical Research in Cardiology</i> , 2011, 100, 327-333.	3.3	16
429	Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 505-513.	3.9	16
430	Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1041-1049.	3.4	16
431	Comparative prognostic value of postprocedural creatine kinase myocardial band and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 215-223.	1.7	16
432	Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis. <i>EuroIntervention</i> , 2021, 17, e388-e395.	3.2	16

#	ARTICLE	IF	CITATIONS
433	Outcomes of patients treated with ultrathin-strut biodegradable polymer sirolimus-eluting stents versus fluoropolymer-based everolimus-eluting stents: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2018, 14, 224-231.	3.2	16
434	Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. <i>American Journal of Cardiology</i> , 2001, 87, 397-400.	1.6	15
435	PIA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2004, 91, 141-145.	3.4	15
436	Genotyping of the Angiotensin I-Converting Enzyme Gene Insertion/Deletion Polymorphism by the TaqMan Method. <i>Clinical Chemistry</i> , 2005, 51, 1547-1549.	3.2	15
437	Accuracy of N-Terminal Pro-Brain Natriuretic Peptide to Predict Mortality in Various Subsets of Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2007, 100, 575-578.	1.6	15
438	Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation? Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1129-1132.	2.9	15
439	Interleukin 18 gene variation and risk of acute myocardial infarction. <i>Cytokine</i> , 2011, 56, 786-791.	3.2	15
440	Chronic dysfunction of the endothelium is associated with mortality in acute coronary syndrome patients. <i>Thrombosis Research</i> , 2013, 131, 198-203.	1.7	15
441	Association of progression or regression of coronary artery atherosclerosis with long-term prognosis. <i>American Heart Journal</i> , 2016, 177, 9-16.	2.7	15
442	High-sensitivity cardiac troponin T and prognosis in patients with ST-segment elevation myocardial infarction. <i>Journal of Cardiology</i> , 2018, 72, 220-226.	1.9	15
443	Inverse association of alanine aminotransferase within normal range with prognosis in patients with coronary artery disease. <i>Clinica Chimica Acta</i> , 2019, 496, 55-61.	1.1	15
444	Monocyte-platelet aggregates affect local inflammation in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 287, 7-12.	1.7	15
445	Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. <i>Cardiovascular Research</i> , 2019, 115, 1512-1518.	3.8	15
446	Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. <i>American Journal of Kidney Diseases</i> , 2004, 44, 627-35.	1.9	15
447	Intracoronary stenting and angiographic results: Restenosis after direct stenting versus stenting with predilation in patients with symptomatic coronary artery disease (ISAR-DIRECT trial). <i>Catheterization and Cardiovascular Interventions</i> , 2004, 61, 190-195.	1.7	14
448	Distal Embolic Protection in Patients With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1116.	7.4	14
449	Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT. A double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. <i>American Heart Journal</i> , 2006, 151, 1248-1254.	2.7	14
450	Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 131-136.	0.8	14

#	ARTICLE	IF	CITATIONS
451	Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. <i>Scientific Reports</i> , 2016, 6, 33054.	3.3	14
452	Incidencia y predictores de la reestenosis recurrente tras angioplastia con balón farmacoactivo en reestenosis de stents farmacoactivos: proyecto cooperativo ICARUS. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 620-627.	1.2	14
453	Subintimal Versus Intraplaque Recanalization of Coronary Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1889-1898.	2.9	14
454	High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2016, 45, 155-161.	1.4	14
455	Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small) Tj ETQq1 1 0.784314.6gBT /Overlock 107	1.4	14
456	EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. <i>Cardiovascular Research</i> , 2007, 77, 580-589.	3.8	13
457	Fibrinogen Genes and Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 758-763.	2.4	13
458	Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 895-902.	1.7	13
459	Variations of specific non-candidate genes and risk of myocardial infarction: A replication study. <i>International Journal of Cardiology</i> , 2011, 147, 38-41.	1.7	13
460	Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 161-166.	1.7	13
461	A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention. <i>Human Molecular Genetics</i> , 2011, 20, 4748-4757.	2.9	13
462	Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. <i>Platelets</i> , 2012, 23, 395-398.	2.3	13
463	Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2013, 165, 537-543.	2.7	13
464	Second-generation versus first-generation sirolimus-eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISAR-TEST4 trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E769-76.	1.7	13
465	Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease. <i>Clinical Research in Cardiology</i> , 2014, 103, 49-56.	3.3	13
466	Prognostic value of thyroid-stimulating hormone within reference range in patients with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1308-1315.	3.4	13
467	Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. <i>Cardiovascular Diabetology</i> , 2016, 15, 124.	6.8	13
468	Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis. <i>Clinical Research in Cardiology</i> , 2019, 108, 1059-1068.	3.3	13

#	ARTICLE	IF	CITATIONS
469	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. <i>Thrombosis and Haemostasis</i> , 2020, 120, 348-362.	3.4	13
470	Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2266-2274.	2.9	13
471	Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery. <i>EuroIntervention</i> , 2019, 15, e1107-e1114.	3.2	13
472	Apolipoprotein E gene polymorphisms and thrombosis and restenosis after coronary artery stenting. <i>Journal of Lipid Research</i> , 2004, 45, 2221-2226.	4.2	12
473	Estimate of myocardial salvage in late presentation acute myocardial infarction by comparing functional and perfusion abnormalities in predischage gated SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 906-911.	6.4	12
474	Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. <i>Clinical Research in Cardiology</i> , 2008, 97, 160-168.	3.3	12
475	Assessment of Platelet Function in Whole Blood by Multiple Electrode Aggregometry: Transport of Samples Using a Pneumatic Tube SystemThe Authorsâ€™ Reply. <i>American Journal of Clinical Pathology</i> , 2009, 132, 802-804.	0.7	12
476	Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1054-1062.	3.4	12
477	No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 429-432.	1.5	12
478	Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. <i>Thrombosis and Haemostasis</i> , 2013, 109, 517-254.	3.4	12
479	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: Results from the ISAR-DESIRE 2 trial. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 69-75.	0.8	12
480	ORAL iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: A patient-level meta-analysis of randomized trials. <i>Atherosclerosis</i> , 2014, 237, 410-417.	0.8	12
481	Drug-eluting stent trials: too much non-inferiority, too little progress?. <i>Lancet, The</i> , 2014, 383, 386-388.	13.7	12
482	Relation of Gamma-Glutamyl Transferase to Cardiovascular Events in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2016, 117, 1427-1432.	1.6	12
483	Association of increased CD8 + and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. <i>Aids</i> , 2016, 30, 1413-1421.	2.2	12
484	Bioresorbable Vascular Scaffold Technology Benefits From Healthy Skepticism. <i>Journal of the American College of Cardiology</i> , 2016, 67, 932-935.	2.8	12
485	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002995.	3.9	12
486	Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the TreatmentÂof Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 477-485.	2.9	12



#	ARTICLE	IF	CITATIONS
487	Standardized Minimalistic Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using the SAPIEN 3 Device: Stepwise Description, Feasibility, and Safety from a Large Consecutive Single-Center Single-Operator Cohort. <i>Structural Heart</i> , 2017, 1, 169-178.	0.6	12
488	A pan-coronary artery angiographic study of the association between diabetes mellitus and progression or regression of coronary atherosclerosis. <i>Heart and Vessels</i> , 2017, 32, 376-384.	1.2	12
489	Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. <i>International Journal of Cardiology</i> , 2018, 258, 42-49.	1.7	12
490	Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2018, 121, 461-468.	1.6	12
491	Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture in Women. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006074.	3.9	12
492	Pathway Analysis Using Genome-Wide Association Study Data for Coronary Restenosis – A Potential Role for the PARVB Gene. <i>PLoS ONE</i> , 2013, 8, e70676.	2.5	12
493	Antiplatelet Therapy Discontinuation and the Risk of Serious Cardiovascular Events after Coronary Stenting: Observations from the CREDO-Kyoto Registry Cohort-2. <i>PLoS ONE</i> , 2015, 10, e0124314.	2.5	12
494	Statin pretreatment and presentation patterns in patients with coronary artery disease. <i>Cardiology Journal</i> , 2013, 20, 52-8.	1.2	12
495	A prospective, non-randomized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis. <i>American Journal of Cardiovascular Disease</i> , 2014, 4, 87-99.	0.5	12
496	Cost Analysis From Two Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in High-Risk Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2006, 48, 262-267.	2.8	11
497	Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives. <i>Current Drug Targets</i> , 2011, 12, 1836-1847.	2.1	11
498	Stents liberadores de rapamicina sin pol�mero frente a stents liberadores de paclitaxel con pol�mero: un an�lisis de datos de pacientes procedentes de ensayos aleatorizados. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 435-442.	1.2	11
499	Anatomic Guided Crossing of a Stenotic Aortic Valve Under Fluoroscopy: ‘‘Right Cusp Rule, Part III’’. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 119-120.	2.9	11
500	Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. <i>Platelets</i> , 2016, 27, 796-804.	2.3	11
501	Prognostic value of alkaline phosphatase in patients with acute coronary syndromes. <i>Clinical Biochemistry</i> , 2017, 50, 828-834.	1.9	11
502	A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2017, 188, 53-64.	2.7	11
503	Gamma-glutamyl transferase and atrial fibrillation in patients with coronary artery disease. <i>Clinica Chimica Acta</i> , 2017, 465, 17-21.	1.1	11
504	Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials. <i>Clinical Research in Cardiology</i> , 2018, 107, 788-798.	3.3	11



#	ARTICLE	IF	CITATIONS
505	Percutaneous coronary intervention: balloons, stents and scaffolds. <i>Clinical Research in Cardiology</i> , 2018, 107, 55-63.	3.3	11
506	One-year clinical outcome with a novel self-expanding transcatheter heart valve. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 783-792.	1.7	11
507	Questions and answers on workup diagnosis and risk stratification: a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1379-1386.	2.2	11
508	A proteomic atlas of the neointima identifies novel druggable targets for preventive therapy. <i>European Heart Journal</i> , 2021, 42, 1773-1785.	2.2	11
509	Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2021, 6, 1121.	6.1	11
510	First use of an expandable sheath and transcaval access for transcatheter Edwards SAPIEN 3 aortic valve implantation. <i>EuroIntervention</i> , 2015, 11, 782-784.	3.2	11
511	Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. <i>Thrombosis and Haemostasis</i> , 2007, 97, 1003-12.	3.4	11
512	A randomized trial comparing the hand-mounted JoStent with the premounted Multi-Link Duet stent in patients with coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 54, 414-419.	1.7	10
513	A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. <i>Clinica Chimica Acta</i> , 2006, 373, 70-76.	1.1	10
514	Glycoprotein IIb/IIIa Receptor Inhibition with Abciximab during Percutaneous Coronary Interventions Increases the Risk of Bleeding in Patients with Impaired Renal Function. <i>Cardiology</i> , 2008, 111, 247-253.	1.4	10
515	Drug-Eluting Stents Versus Bare-Metal Stents in Diabetic Patients With ST-Segment Elevation Acute Myocardial Infarction: A Pooled Analysis of Individual Patient Data From 7 Randomized Trials. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2009, 62, 354-364.	0.6	10
516	Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy. <i>Clinical Research in Cardiology</i> , 2010, 99, 13-19.	3.3	10
517	Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. <i>Thrombosis and Haemostasis</i> , 2012, 107, 769-774.	3.4	10
518	C-reactive protein and prognosis in women and men with coronary artery disease after percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 264-269.	0.8	10
519	Two Rare Variants Explain Association with Acute Myocardial Infarction in an Extended Genomic Region Including the Apolipoprotein(A) Gene. <i>Annals of Human Genetics</i> , 2013, 77, 47-55.	0.8	10
520	Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2014, 175, 484-491.	1.7	10
521	Hospital admissions with acute coronary syndromes during the COVID-19 pandemic in German cardiac care units. <i>Cardiovascular Research</i> , 2020, 116, 1800-1801.	3.8	10
522	Apolipoprotein E gene $\epsilon$ 2/ $\epsilon$ 3/ $\epsilon$ 4 polymorphism and myocardial infarction: Case-control study in a large population sample. <i>International Journal of Cardiology</i> , 2008, 125, 116-117.	1.7	9

#	ARTICLE	IF	CITATIONS
523	Intravenous $\beta$ -Blockers in Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2013, 128, 1487-1489.	1.6	9
524	Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. <i>American Heart Journal</i> , 2014, 168, 862-868.e1.	2.7	9
525	Vascular response to percutaneous coronary intervention with biodegradable-polymer vs. new-generation durable-polymer drug-eluting stents: a meta-analysis of optical coherence tomography imaging trials. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 1294-1301.	1.2	9
526	Creatine kinase myocardial band - a biomarker to assess prognostically relevant periprocedural myocardial infarction. <i>International Journal of Cardiology</i> , 2018, 270, 118-119.	1.7	9
527	Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis. <i>International Journal of Cardiology</i> , 2019, 276, 212-217.	1.7	9
528	Relation of Ratio of Left Ventricular Ejection Fraction to Left Ventricular End-Diastolic Pressure to Long-Term Prognosis After ST-Segment Elevation Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2019, 123, 199-205.	1.6	9
529	Hybrid PET/MR imaging for the prediction of left ventricular recovery after percutaneous revascularisation of coronary chronic total occlusions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3074-3083.	6.4	9
530	Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e018304.	3.7	9
531	Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). <i>Cardiovascular Revascularization Medicine</i> , 2022, 34, 17-24.	0.8	9
532	Tools and Techniques - Clinical: Fluoroscopic balloon sizing of the aortic annulus before transcatheter aortic valve replacement (TAVR) â€” follow the â€œright cusp ruleâ€. <i>EuroIntervention</i> , 2015, 11, 840-842.	3.2	9
533	Sex-associated differences in clinical outcomes after coronary stenting in patients with diabetes mellitus. <i>American Journal of Medicine</i> , 2004, 117, 830-836.	1.5	8
534	Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 511-515.	1.0	8
535	Is there a preferable DES in diabetic patients? A critical appraisal of the evidence. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 944-949.	1.7	8
536	Serum potassium levels on admission and infarct size in patients with acute myocardial infarction. <i>Clinica Chimica Acta</i> , 2009, 409, 46-51.	1.1	8
537	Unmet Aspirations â€” Where To Now for Catheter Thrombectomy?. <i>New England Journal of Medicine</i> , 2013, 369, 1649-1650.	27.0	8
538	Prognostic value of gamma-glutamyl transferase in patients with diabetes mellitus and coronary artery disease. <i>Clinical Biochemistry</i> , 2016, 49, 1127-1132.	1.9	8
539	Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2548-2556.	2.9	8
540	Incidental findings in multislice computed tomography prior to transcatheter aortic valve implantation: frequency, clinical relevance and outcome. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 985-992.	1.5	8

#	ARTICLE	IF	CITATIONS
541	Endovascular Treatment for Steno-Occlusive Iliac Artery Disease: Safety and Long-Term Outcome. <i>Angiology</i> , 2018, 69, 308-315.	1.8	8
542	Relationship of left ventricular end-diastolic pressure with extent of myocardial ischemia, myocardial salvage and long-term outcome in patients with ST-segment elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 901-909.	1.7	8
543	In-Stent Restenosis in the United States. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1532-1535.	2.8	8
544	Guided P2Y12 inhibitor therapy after percutaneous coronary intervention. <i>Lancet</i> , The, 2021, 397, 1423-1425.	13.7	8
545	Clinical burden and implications of coronary interventions for in-stent restenosis. <i>EuroIntervention</i> , 2021, 17, e355-e357.	3.2	8
546	Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction. <i>EuroIntervention</i> , 2011, 7, 128-135.	3.2	8
547	Lack of Benefit From Nitric Oxide Synthase Inhibition in Patients With Cardiogenic Shock. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1711.	7.4	7
548	Impact of Myocardial Salvage Assessed by 99mTc-Sestamibi Scintigraphy on Cardiac Autonomic Function in Patients Undergoing Mechanical Reperfusion Therapy for Acute Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 449-457.	5.3	7
549	Myocardial Perfusion Grade, Myocardial Salvage Indices and Long-Term Mortality in Patients With Acute Myocardial Infarction and Full Restoration of Epicardial Blood Flow After Primary Percutaneous Coronary Intervention. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2010, 63, 770-778.	0.6	7
550	Extended evidence for association between the melanoma inhibitory activity 3 gene and myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2011, 105, 670-675.	3.4	7
551	Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. <i>Clinical Research in Cardiology</i> , 2011, 100, 691-699.	3.3	7
552	New anti-platelet agents: The end of resistance?. <i>Thrombosis Research</i> , 2012, 130, S53-S55.	1.7	7
553	A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. <i>Platelets</i> , 2013, 24, 15-25.	2.3	7
554	Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 367-374.	1.7	7
555	Predicting factors for long-term survival in patients with out-of-hospital cardiac arrest – A propensity score-matched analysis. <i>PLoS ONE</i> , 2020, 15, e0218634.	2.5	7
556	Sex and long-term outcomes after implantation of the Absorb bioresorbable vascular scaffold for treatment of coronary artery disease. <i>EuroIntervention</i> , 2019, 15, 615-622.	3.2	7
557	Not all drug-eluting balloons are equally good for patients, not all patients are equally suitable for drug-eluting balloons. <i>EuroIntervention</i> , 2012, 8, 417-421.	3.2	7
558	720-6 Stenting for Progressive Dissection During PTCA: Clinical, Angiographic and Intravascular Ultrasound Criteria to Define a Low-risk Group not Requiring Subsequent Anticoagulation. <i>Journal of the American College of Cardiology</i> , 1995, 25, 123A-124A.	2.8	6

#	ARTICLE	IF	CITATIONS
559	Sustained increased risk of adverse cardiac events over 5 years after implantation of gold-coated coronary stents. Catheterization and Cardiovascular Interventions, 2006, 68, 690-695.	1.7	6
560	ISAR - A Story of Trials With Impact on Practice -. Circulation Journal, 2010, 74, 1771-1778.	1.6	6
561	Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention. Heart and Vessels, 2010, 25, 294-298.	1.2	6
562	New-Generation Drug-Eluting Stents for Patients With Myocardial Infarction. JAMA - Journal of the American Medical Association, 2012, 308, 814.	7.4	6
563	Correlates of poor outcome among patients with bleeding after coronary interventions. Coronary Artery Disease, 2014, 25, 456-462.	0.7	6
564	Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?. Journal of Thoracic Disease, 2016, 8, E417-E423.	1.4	6
565	Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). Thrombosis Research, 2016, 137, 72-78.	1.7	6
566	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. International Journal of Cardiology, 2018, 263, 24-28.	1.7	6
567	Incidence and predictors of reCurrent restenosis after drug-coated balloon Angioplasty for Restenosis of a drUg-eluting Stent: The ICARUS Cooperation. Revista Espanola De Cardiologia (English) Tj ETQq1 1 0.784314rgBT /Ov	0.7	6
568	Genetic testing to guide therapy? Not for ticagrelor!. European Heart Journal, 2019, 40, e1-e3.	2.2	6
569	Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery diseaseâ€”A meta-analysis of randomized clinical trials. American Heart Journal, 2020, 219, 109-116.	2.7	6
570	Clinical outcomes of complete versus incomplete revascularization in patients treated with coronary artery bypass grafting: insights from the TiCAB trial. European Journal of Cardio-thoracic Surgery, 2021, 59, 417-425.	1.4	6
571	Harnessing feature extraction capacities from a pre-trained convolutional neural network (VGG-16) for the unsupervised distinction of aortic outflow velocity profiles in patients with severe aortic stenosis. European Heart Journal Digital Health, 2022, 3, 153-168.	1.7	6
572	Leucine 7 to Proline 7 Polymorphism of the Preproneuropeptide Y Gene is Not Associated with Restenosis after Coronary Stenting. Journal of Endovascular Therapy, 2003, 10, 566-572.	1.5	5
573	Iron status and clinical outcome in patients with coronary artery disease after coronary stenting. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 418-425.	2.6	5
574	Effect of Abciximab on Clinical and Angiographic Restenosis in Patients With Nonâ€”ST-Segment Elevation Acute Coronary Syndromes. American Journal of Cardiology, 2008, 101, 1226-1231.	1.6	5
575	The Only Better Alternative to Rescue Percutaneous Coronary Intervention Is Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2009, 54, 127-129.	2.8	5
576	Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction. Thrombosis and Haemostasis, 2010, 103, 638-643.	3.4	5

#	ARTICLE	IF	CITATIONS
577	Lost contact with vessel wall, signed contract with stent thrombosis?. European Heart Journal, 2012, 33, 1305-1308.	2.2	5
578	Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. Coronary Artery Disease, 2014, 25, 658-664.	0.7	5
579	Procedure-related bleeding in elective percutaneous coronary interventions. European Journal of Clinical Investigation, 2015, 45, 263-273.	3.4	5
580	Fluoroscopic calcification-guided optimal deployment projection during transcatheter aortic valve replacement – “The eye of the pigtail.” (Follow the right cusp rule – Part II). Catheterization and Cardiovascular Interventions, 2016, 87, 996-998.	1.7	5
581	Postprocedural high-sensitivity troponin T and prognosis in patients with non-ST-segment elevation myocardial infarction treated with early percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2018, 19, 480-486.	0.8	5
582	Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease. Annals of Thoracic Surgery, 2022, 113, 554-562.	1.3	5
583	Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e020165.	3.7	5
584	Primary PCI, Late Presenting STEMI, and the Limits of Time. Journal of the American College of Cardiology, 2021, 78, 1306-1308.	2.8	5
585	Long-term clinical outcomes after drug eluting stent implantation with and without stent overlap. Catheterization and Cardiovascular Interventions, 2022, 99, 541-551.	1.7	5
586	Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1117-1124.	1.0	5
587	Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI). Journal of Invasive Cardiology, 2005, 17, 199-202.	0.4	5
588	Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. Thrombosis and Haemostasis, 2009, 101, 340-4.	3.4	5
589	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. Revista Espanola De Cardiologia (English Ed ), 2022, , .	0.6	5
590	Primary intracoronary stenting in acute myocardial infarction: Long-term clinical and angiographic follow-up and risk factor analysis. American Heart Journal, 2000, 139, 0208-0216.	2.7	5
591	Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2022, 11, e023493.	3.7	5
592	Rotational atherectomy of calcified coronary lesions: current practice and insights from two randomized trials. Clinical Research in Cardiology, 2022, , .	3.3	5
593	Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement. Atherosclerosis, 2003, 166, 171-176.	0.8	4
594	Pharmacological prevention and management of restenosis. Expert Opinion on Pharmacotherapy, 2010, 11, 1855-1872.	1.8	4

#	ARTICLE	IF	CITATIONS
595	The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Expert Review of Cardiovascular Therapy, 2011, 9, 999-1014.	1.5	4
596	Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. Clinical Research in Cardiology, 2011, 100, 579-585.	3.3	4
597	SORT OUT V: a new episode in the DES wars. Lancet, The, 2013, 381, 609-611.	13.7	4
598	Collagen Plug Vascular Closure Devices and Reduced Risk of Bleeding with Bivalirudin Versus Heparin Plus Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Non <sc>ST</sc>-segment Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2013, 26, 623-629.	1.2	4
599	Activated Clotting Time During Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	4
600	Prognostic Value of High-sensitivity Troponin T After Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 746-753.	0.6	4
601	Bifurcation intervention with a two-stent strategy: can one size fit all?. European Heart Journal, 2016, 37, 3406-3408.	2.2	4
602	Cardiogenic Shock. Journal of the American College of Cardiology, 2016, 67, 748-750.	2.8	4
603	Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-MAIN and ISAR-MAIN 2 randomized clinical trials. Catheterization and Cardiovascular Interventions, 2017, 89, 1-10.	1.7	4
604	Rebuttal: Comparative prognostic value of postprocedural creatine kinase myocardial band and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2018, 92, 635-636.	1.7	4
605	What Treatment Should We Dare in Patients With In-Stent Restenosis?. JACC: Cardiovascular Interventions, 2018, 11, 284-286.	2.9	4
606	Strengths and Limitations of Real World Data in Patients Treated With Coronary Stents. Circulation: Cardiovascular Interventions, 2018, 11, e007239.	3.9	4
607	Progress in Drug-Eluting Stent Technology. JACC: Cardiovascular Interventions, 2019, 12, 1661-1664.	2.9	4
608	Efficacy of drug-coated balloon angioplasty in early versus late occurring drug-eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials. Catheterization and Cardiovascular Interventions, 2020, 96, 1008-1015.	1.7	4
609	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2021, 14, e010565.	3.9	4
610	Meeting report ESC Forum on Drug Eluting Stents, European Heart House, Nice, 27-28 September 2007. EuroIntervention, 2009, 4, 427-436.	3.2	4
611	Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease. Indian Journal of Medical Research, 2014, 140, 392-400.	1.0	4
612	Prognostic impact of secondary prevention after coronary artery bypass grafting—insights from the TiCAB trial. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	4



#	ARTICLE	IF	CITATIONS
613	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120009495.	3.9	4
614	Myocardial Salvage after Reduced-Dose Thrombolysis Combined with Glycoprotein IIb/IIIa Blockade Versus Thrombolysis Alone in Patients with Acute Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 17, 191-197.	2.1	3
615	Drug for a while, polymer for life: Is it a good solution?. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 340-341.	1.7	3
616	Treatment of Paclitaxel-Eluting Stent Restenosis With Sirolimus-Eluting Stent Implantation—Angiographic and Clinical Outcomes. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2008, 61, 1134-1139.	0.6	3
617	Ruptured versus stable plaques in human coronary arteries. <i>Coronary Artery Disease</i> , 2011, 22, 345-351.	0.7	3
618	Stratification of coronary artery disease patients for revascularization procedure based on estimating adverse effects. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 9.	3.0	3
619	Prognosis after revascularization for left main coronary artery disease: insights from the crystal ball. <i>European Heart Journal</i> , 2015, 36, 1212-1215.	2.2	3
620	Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	3
621	Drug-Eluting Balloons or Stents for Bare-Metal Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1256-1258.	2.9	3
622	Implantation of a MitraClip between two previously implanted MitraClips to treat recurrent severe mitral regurgitation. <i>Journal of Cardiology Cases</i> , 2017, 15, 50-52.	0.5	3
623	Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 57, 520-528.	1.4	3
624	U-shaped association of central pulse pressure with long-term prognosis after ST-segment elevation myocardial infarction. <i>Heart and Vessels</i> , 2019, 34, 1104-1112.	1.2	3
625	Long-Term Ticagrelor Versus Prasugrel Pharmacodynamics in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e015726.	3.7	3
626	Ultrasound-guided thrombin injection for treatment of femoral artery pseudoaneurysm with concomitant AV-fistula – a retrospective single centre experience. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 507-512.	1.4	3
627	A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. <i>Thrombosis and Haemostasis</i> , 2005, 93, 789-91.	3.4	3
628	Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial. <i>EuroIntervention</i> , 2022, 17, 1348-1351.	3.2	3
629	Restenosis in one lesion in patients with multilesion stenting occurs even when the companion lesion is free of restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 53, 287-287.	1.7	2
630	Polymer-free Sirolimus-eluting Versus Polymer-based Paclitaxel-eluting Stents: An Individual Patient Data Analysis of Randomized Trials. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2013, 66, 435-442.	0.6	2



#	ARTICLE	IF	CITATIONS
631	Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality. <i>European Heart Journal</i> , 2013, 34, 872-874.	2.2	2
632	Duration of Dual Antiplatelet Therapy After Drug-eluting Stents Implantation: The Jury Is Still Out. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 827-829.	0.6	2
633	Polymer-free drug-eluting stents â€” a safe and effective option for ACS. <i>Nature Reviews Cardiology</i> , 2016, 13, 447-448.	13.7	2
634	Molecular multimodality imaging: has a long-standing dream come true?. <i>European Heart Journal</i> , 2016, 38, ehv768.	2.2	2
635	Evaluation of a Low-Dose Radiation Protocol During Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 139, 71-78.	1.6	2
636	Antithrombotic treatment in primary percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 313-324.	1.5	2
637	Prediction of risk for bleeding, myocardial infarction and mortality after percutaneous coronary intervention in patients with acute coronary syndromes. <i>Coronary Artery Disease</i> , 2022, Publish Ahead of Print, .	0.7	2
638	Periprocedural myocardial injury according to optical characteristics of neointima and treatment modality of in-stent restenosis. <i>Clinical Research in Cardiology</i> , 2022, 111, 827-837.	3.3	2
639	Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial. <i>Clinical Research in Cardiology</i> , 2023, 112, 518-528.	3.3	2
640	Impact of acute myocardial infarct location on myocardial salvage after stenting or thrombolysis (results from the STOPAMI 1 and 2 trials): Stent versus Thrombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2003, 91, 341-343.	1.6	1
641	Drug-eluting stents for secondary prevention of restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 63, 265-266.	1.7	1
642	New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective. <i>Country Review Ukraine</i> , 2007, 9, A4-A10.	0.8	1
643	Are sirolimus-eluting stents superior to paclitaxel-eluting stents in patients with small-vessel disease?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 188-189.	3.3	1
644	Is diabetes a leveler of efficacy of DES types?. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 335-337.	1.7	1
645	In the Bivalirudin Era, Are We Still Looking for a Potent Antiplatelet Agent?. <i>Current Vascular Pharmacology</i> , 2012, 10, 476-478.	1.7	1
646	Contemporary drug-eluting stents and companion polymers: durable is not synonymous with harm. <i>Journal of Thoracic Disease</i> , 2016, 8, E1413-E1415.	1.4	1
647	Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients. <i>Coronary Artery Disease</i> , 2016, 27, 385-390.	0.7	1
648	Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 906-915.	1.9	1

#	ARTICLE	IF	CITATIONS
649	Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 57, 732-739.	1.4	1
650	Relation of Hypcholesterolemia With Diabetes Mellitus in Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2020, 125, 1026-1032.	1.6	1
651	Angiographic performance of everolimus-eluting stents for the treatment of coronary in-stent restenosis in daily practice. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 857-862.	1.7	1
652	SARS-CoV-2 Infection in Asymptomatic Patients Hospitalized for Cardiac Emergencies: Implications for Patient Management. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 599299.	2.4	1
653	Mechanistic insights into the superior clinical efficacy of prasugrel over ticagrelor. <i>European Heart Journal</i> , 2020, 41, 3153-3155.	2.2	1
654	Anatomic and Flow Characteristics of Left Anterior Descending Coronary Artery Angiographic Stenoses Predisposing to Myocardial Infarction. <i>American Journal of Cardiology</i> , 2021, 141, 7-15.	1.6	1
655	Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2021, 338, 8-13.	1.7	1
656	Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2021, 10, e021418.	3.7	1
657	Preadmission antiplatelet therapy and treatment effect of ticagrelor versus prasugrel in patients with acute coronary syndromes - a subgroup analysis of the ISAR-REACT 5 trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, , .	3.0	1
658	Critical role of bare-metal stent controls in trials of drug-eluting stents: reply. <i>European Heart Journal</i> , 2005, 26, 1687-1687.	2.2	0
659	Is there a role for oral rapamycin in restenosis prevention after bare-metal stent implantation?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 476-477.	3.3	0
660	Is it naive to load only clopidogrel-naïve patients prior to PCI?. <i>European Heart Journal</i> , 2010, 31, 1298-1300.	2.2	0
661	Response from the authors to: The value of elevated high-sensitivity troponin T. <i>American Heart Journal</i> , 2011, 161, e35.	2.7	0
662	Treatment of coronary drug-eluting stent restenosis: a journey back to the future?. <i>Expert Review of Medical Devices</i> , 2013, 10, 423-427.	2.8	0
663	Drug-eluting stents for drug-eluting stent restenosis. <i>Coronary Artery Disease</i> , 2014, 25, 633-635.	0.7	0
664	Optimal periprocedural antithrombotic therapy in percutaneous coronary intervention: Between a rock and a hard place?. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 491-493.	0.8	0
665	Response to the letter to the editor: Mortality risk of elevated alkaline phosphatase in patients with coronary artery disease and percutaneous coronary intervention. <i>Clinical Biochemistry</i> , 2017, 50, 1328-1329.	1.9	0
666	Bioresorbable vascular scaffolds for complex coronary anatomies: the CARUS <sup>TM</sup> flight <sup>®</sup> for interventional cardiologists?. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, S98-S101.	1.7	0

#	ARTICLE	IF	CITATIONS
667	Patent foramen ovale closure for patients excluded from the randomized cryptogenic stroke trials: response to letter by Zaman et al.. Clinical Research in Cardiology, 2018, 107, 1189-1191.	3.3	0
668	High-sensitivity cardiac troponin T in patients with ST-segment elevation myocardial infarction. Journal of Cardiology, 2019, 73, 333-334.	1.9	0
669	Optical Coherence Tomography Tissue Coverage and Characterization with Grey-Scale Signal Intensity Analysis After Bifurcation Stenting with a New Generation Bioabsorbable Polymer Drug-Eluting Stent. Cardiovascular Revascularization Medicine, 2020, 21, 277-285.	0.8	0
670	Reply. Journal of the American College of Cardiology, 2020, 76, 1392-1393.	2.8	0
671	Outcomes after complete dissolution of everolimus-eluting bioresorbable scaffolds implanted during routine practice. Revista Espanola De Cardiologia (English Ed ), 2020, 74, 584-590.	0.6	0
672	The Bayesian Approach and the Results of the ISAR-REACT 5 Trial. JACC: Cardiovascular Interventions, 2021, 14, 231-232.	2.9	0
673	Letter by Kessler et al Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52,816 Patients From 12 Randomized Trials", Circulation, 2021, 143, e230-e231.	1.6	0
674	Stent Thrombosis in Patients Treated for Acute or Chronic Coronary Syndrome. JACC: Cardiovascular Interventions, 2021, 14, 1091-1093.	2.9	0
675	Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention. Future Cardiology, 2021, 17, 539-547.	1.2	0
676	Drug-Eluting Stent. , 2010, , 114-122.		0
677	A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol. EuroIntervention, 2010, 5, 976-980.	3.2	0
678	Primary Percutaneous Coronary Intervention. , 2010, , 65-77.		0
679	Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. EuroIntervention, 2016, 11, e1275-e1282.	3.2	0
680	Investigator-driven randomized trials. , 2017, , 272-282.		0
681	Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes. Revista Espanola De Cardiologia (English Ed ), 2021, , .	0.6	0